119 related articles for article (PubMed ID: 17404018)
1. Combination of doxorubicin and sulforaphane for reversing doxorubicin-resistant phenotype in mouse fibroblasts with p53Ser220 mutation.
Fimognari C; Lenzi M; Sciuscio D; Cantelli-Forti G; Hrelia P
Ann N Y Acad Sci; 2007 Jan; 1095():62-9. PubMed ID: 17404018
[TBL] [Abstract][Full Text] [Related]
2. Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations.
Fimognari C; Nüsse M; Lenzi M; Sciuscio D; Cantelli-Forti G; Hrelia P
Mutat Res; 2006 Oct; 601(1-2):92-101. PubMed ID: 16843502
[TBL] [Abstract][Full Text] [Related]
3. A mutated p53 status did not prevent the induction of apoptosis by sulforaphane, a promising anti-cancer drug.
Fimognari C; Sangiorgi L; Capponcelli S; Nüsse M; Fontanesi S; Berti F; Soddu S; Cantelli-Forti G; Hrelia P
Invest New Drugs; 2005 Jun; 23(3):195-203. PubMed ID: 15868375
[TBL] [Abstract][Full Text] [Related]
4. Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent.
Choi S; Singh SV
Cancer Res; 2005 Mar; 65(5):2035-43. PubMed ID: 15753404
[TBL] [Abstract][Full Text] [Related]
5. Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy.
Pastorek M; Simko V; Takacova M; Barathova M; Bartosova M; Hunakova L; Sedlakova O; Hudecova S; Krizanova O; Dequiedt F; Pastorekova S; Sedlak J
Int J Oncol; 2015 Jul; 47(1):51-60. PubMed ID: 25955133
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane.
Fimognari C; Nüsse M; Cesari R; Iori R; Cantelli-Forti G; Hrelia P
Carcinogenesis; 2002 Apr; 23(4):581-6. PubMed ID: 11960909
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane modulates cell cycle and apoptosis in transformed and non-transformed human T lymphocytes.
Fimognari C; Nüsse M; Berti F; Iori R; Cantelli-Forti G; Hrelia P
Ann N Y Acad Sci; 2003 Dec; 1010():393-8. PubMed ID: 15033759
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D3 and p53 mediate sulforaphane-induced cell cycle delay and apoptosis in non-transformed human T lymphocytes.
Fimognari C; Nüsse M; Berti F; Iori R; Cantelli-Forti G; Hrelia P
Cell Mol Life Sci; 2002 Nov; 59(11):2004-12. PubMed ID: 12530531
[TBL] [Abstract][Full Text] [Related]
9. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
10. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
[TBL] [Abstract][Full Text] [Related]
11. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy.
Tergaonkar V; Pando M; Vafa O; Wahl G; Verma I
Cancer Cell; 2002 Jun; 1(5):493-503. PubMed ID: 12124178
[TBL] [Abstract][Full Text] [Related]
12. HSP27 regulates p53 transcriptional activity in doxorubicin-treated fibroblasts and cardiac H9c2 cells: p21 upregulation and G2/M phase cell cycle arrest.
Venkatakrishnan CD; Dunsmore K; Wong H; Roy S; Sen CK; Wani A; Zweier JL; Ilangovan G
Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1736-44. PubMed ID: 18263706
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation.
Capponcelli S; Pedrini E; Cerone MA; Corti V; Fontanesi S; Alessio M; Bachi A; Soddu S; Ribatti D; Picci P; Helman LJ; Cantelli-Forti G; Sangiorgi L
Hum Mutat; 2005 Aug; 26(2):94-103. PubMed ID: 15977174
[TBL] [Abstract][Full Text] [Related]
14. Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling.
Dunkern TR; Wedemeyer I; Baumgärtner M; Fritz G; Kaina B
DNA Repair (Amst); 2003 Jan; 2(1):49-60. PubMed ID: 12509267
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
Robles AI; Wright MH; Gandhi B; Feis SS; Hanigan CL; Wiestner A; Varticovski L
Clin Cancer Res; 2006 Nov; 12(21):6547-56. PubMed ID: 17085670
[TBL] [Abstract][Full Text] [Related]
16. Restoration of wild-type p53 in drug-resistant mouse breast cancer cells leads to differential gene expression, but is not sufficient to overcome the malignant phenotype.
Gottschalk B; Klein A
Mol Cell Biochem; 2013 Jul; 379(1-2):213-27. PubMed ID: 23564067
[TBL] [Abstract][Full Text] [Related]
17. Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells.
Rong Y; Huang L; Yi K; Chen H; Liu S; Zhang W; Yuan C; Song X; Wang F
Cancer Lett; 2020 Nov; 493():189-196. PubMed ID: 32891712
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines.
Lee TK; Lau TC; Ng IO
Cancer Chemother Pharmacol; 2002 Jan; 49(1):78-86. PubMed ID: 11855756
[TBL] [Abstract][Full Text] [Related]
19. RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells.
Mukhopadhyay UK; Senderowicz AM; Ferbeyre G
Cancer Res; 2005 Apr; 65(7):2872-81. PubMed ID: 15805289
[TBL] [Abstract][Full Text] [Related]
20. Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice.
Conaway CC; Wang CX; Pittman B; Yang YM; Schwartz JE; Tian D; McIntee EJ; Hecht SS; Chung FL
Cancer Res; 2005 Sep; 65(18):8548-57. PubMed ID: 16166336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
